PROCEPT BioRobotics Launches AI-Enabled HYDROS System in UK, Plans 2026 Expansion
PROCEPT BioRobotics has launched its AI-enabled HYDROS Robotic System in the UK, marking the first international rollout of its next-generation Aquablation therapy platform. The company plans further international expansion in 2026 to broaden access to ultrasound-guided, robotic-assisted BPH treatment.
1. International Launch in the UK
PROCEPT BioRobotics deployed the HYDROS Robotic System in the United Kingdom on March 12, 2026, marking the first time its AI-enabled Aquablation platform is used outside the U.S. This rollout introduces UK surgeons and patients to real-time ultrasound-guided, robotic-assisted waterjet therapy for benign prostatic hyperplasia (BPH).
2. Advanced AI-Enabled Platform
The HYDROS system leverages AI-interpreted ultrasound imaging and advanced image-guided planning to deliver personalized, anatomy-specific prostate tissue removal with robotic precision. The heat-free waterjet approach is designed to preserve sexual and urinary function while providing durable symptom relief.
3. Plans for Further Global Expansion
Building on the UK launch, PRCT intends to extend HYDROS availability to additional international markets throughout 2026. The phased expansion aims to broaden surgical choice for men with BPH and support scalable adoption across diverse care settings.